top of page
  • Recruiting
    • Apr 26, 2022

NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release

Updated: Sep 8, 2022


NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

cilta-cel cart myeloma janssen

The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).


Sponsor

Janssen Scientific Affairs, LLC

 

ClinicalTrials.gov Identifier: NCT05347485


Official Title: A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma

First Posted: April 26, 2022


Click here for details on ClinicalTrials.gov


A Study of JNJ-68284528 Out‐of‐Specification (OOS) for Commercial Release in Participants with Multiple Myelom